Loading insider details...
Beta
Latest Form 4 (Mar 4, 2026): Grant/Award of 268,176 EIKN shares.
Every alert includes an AI-written analysis of the filing, plus news and market context.
| Filed | Company | Transaction | Shares | Value |
|---|---|---|---|---|
| Mar 4, 2026 | Eikon Therapeutics, Inc. (EIKN) | Grant/Award | 268,176 | n/a |
| Feb 10, 2026 | Eikon Therapeutics, Inc. (EIKN) | Conversion | 284,857 | n/a |
| Apr 8, 2024 | NGM BIOPHARMACEUTICALS INC (NGM) | Disposition to Issuer | 78,407 | n/a |
| May 5, 2020 | Merck & Co., Inc. (MRK) | Grant/Award | 151,029 | n/a |
| Mar 3, 2020 | Merck & Co., Inc. (MRK) | Grant/Award | 35,049 | $2.68M |
| May 7, 2019 | Merck & Co., Inc. (MRK) | Unknown | 141,134 | n/a |
| Feb 27, 2019 | Merck & Co., Inc. (MRK) | Grant/Award | 32,937 | $2.65M |
| Nov 8, 2018 | Merck & Co., Inc. (MRK) | Exercise/Conversion | 225,443 | $10.14M |
| May 8, 2018 | Merck & Co., Inc. (MRK) | Unknown | 146,383 | n/a |
| Mar 2, 2018 | Merck & Co., Inc. (MRK) | Grant/Award | 34,931 | $1.91M |